Search This Blog

Thursday, June 25, 2015

UK Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit (NYSE:LLY)

INDIANAPOLISJune 25, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Court of Appeal has ruled that the Alimta® (pemetrexed disodium) vitamin regimen patent would be indirectly infringed by a generic competitor that had stated its intent to market certain alternative salt forms of pemetrexed in the United Kingdom prior to the UK patent's expiration in June 2021.
Specifically, the Court of Appeal held that commercialization of these alternative salt forms in the products as proposed would constitute indirect infringement by supplying an essential means for putting the patented invention into effect. The decision came in the case of Actavis v. Eli Lilly and Company.


UK Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit (NYSE:LLY)

No comments:

Post a Comment